Abstract
Although known to be one of the most chemoresponsive and radiosensitive solid tumors in adult patients, small-cell lung carcinoma (SCLC) still has a particularly poor prognosis, with a 2-year survival not exceeding 10% in most series [1–4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Davis S, Wright PW, Schulman SF, Scholes D, Thorning D, and Hammar S. Long-term survival in small cell carcinoma of the lung: a population experience. J Clin Oncol 3:80–91, 1985.
Hansen M, Hansen HH, and Dombernowsky P. Long-term survival in small cell carcinoma of the lung. JAMA 244:247–250, 1980.
Lee JS, Unsawasdi T, Lee Y, Barkley HT, Murphy WK, Welch S, and Valdivieso M. Neurotoxicity in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys 12:313–321, 1984.
Souhami RL, Geddes DM, Spiro SG, Harper PG, Tobias JS, Mantell BS, Fearon F, and Bradbury I. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J 288:1643–1646, 1984.
Maurer LH and Pajak TF. Prognostic factors in small cell carcinoma of the lung: a Cancer and Leukemia Group B study. Cancer Treat Rep 65:767–774, 1981.
Harper PG, Souhami RL, Spiro SG, Geddes DM, Guimaraes M, Fearon F, and Smyth JF. Tumor size, response rate and prognosis in small cell carcinoma of the bronchus treated by combination chemotherapy. Cancer Treat Rep 66:463–470, 1982.
Osterlind K, Hansen HH, Hansen M, Dombernowsky P, and Andersen PK. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 4:1307–1313, 1986.
Tubiana M, Arriagada R, Carde P, Cosset JM, and Le Chevalier T. Adjuvant radiotherapy in chemosensitive tumors. In: Adjuvant Therapy of Cancer V, SE Salmon (ed). Grune & Stratton, Orlando, pp. 25–34.
Choi NC, Propert K, Carey RW, Eaton W, Leone LA, Silberfarb P, and Green M. Accelerated radiotherapy followed by chemotherapy for locally recurrent small-cell carcinoma of the lung. A phase II study of Cancer and Leukemia Group B. Int J Radiat Oncol Biol Phys 13:263–266, 1987.
Rubin P. Late effects of chemotherapy and radiation therapy: a new hypothesis. Int J Radiat Oncol Biol Phys 19:5–34, 1984.
Lagrange JL, Thyss A, Caldani C, Hery M, Schneider M, and Bensadoun JR. Toxicity of combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin disease patients with massive initial mediastinal involvement. Bull Cancer 75:801–806, 1988.
Tubiana M, Arriagada R, and Cosset JM. Sequencing of drugs and radiation. Cancer 55:2131–2139, 1985.
Fu KK. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer 55:2123–2130, 1985.
Von Der Maase H. Experimental studies on interactions of radiation and cancer chemotherapeutic drugs in normal tissues and a solid tumor. Radiother Oncol 7:47–68, 1986.
Steel GC. The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother Oncol 11:31–53, 1988.
Tubiana M. Les associations radiothérapie-chimiothérapie. Bull Cancer 68:109–115, 1981.
Looney WB and Hopkins HA. Alternation of chemotherapy and radiotherapy in cancer management. III. Results in experimental solid tumors systems and their relationship to clinical studies. Cancer Treat Rep 70:141–162, 1986.
Tubiana M. Repopulation in human tumors. A biological background for fractionation in radiotherapy. Acta Oncol 27:83–88, 1988.
Withers HR, Taylor JMG, and Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131–146, 1988.
Schimke RT. Methotrexate resistance and gene amplification. Mechanisms and implications. In: Accomplishments in Cancer Research, JG Fortner and JE Rhoads (eds), JB Lippincott, Philadelphia, 1986, pp. 75.
Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, and Ozols RF. Radiation survival parameters of antineoplastic drug-sensitive and resistant human ovarian cancer cell lines and their modification by buthionine. Cancer Res 45:2110–2115, 1985.
Mitchell JB, Gamson J, Russo A, Friedman N, Degraff W, Carmichael J, and Glatstein E. Chinese hamster pleiotropic multidrug resistant cells are not radioresistant. NCI Monogr 6:187–191, 1988.
Wallner K and Li GC. Adriamycin resistance, heat resistance and radiation response in Chinese hamster fibroblasts. Int J Rad Oncol Biol Phys 12:829–833, 1986.
Goldie GH and Coldman AG. The genetic origin of drug resistance in neoplasm: implications for systemic therapy. Cancer Res 44:3643–3663, 1984.
Fox RM, Woods RL, Brodie GN, and Tattersall MHN. A randomized study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy. Int J Rad Oncol Biol Phys 6:1083–1085, 1980.
Kies MS, Mira JG, Crowley JJ, Chen TT, Pazdur R, Grozea PN, Rivkin SE, Coltman CA, Ward JH, and Livingston RB. Multimodal therapy for limited small cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide field versus reduced field radiation in partial responders: a Southwest Oncology Group study. J Clin Oncol 5:592–600, 1987.
Creech R, Richter M, and Finkelstein D, for the ECOG. Combination chemotherapy with or without consolidation radiation therapy (RT) for regional small cell carcinoma of the lung. Proc Am Soc Clin Oncol, abstract 756, 1988.
Osterlind K, Hansen HH, Hansen HS, Dombernovsky P, Hansen M, and Rorth M. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer: results of a controlled trial with 5 years’ follow-up. Br J Cancer 54:7–17, 1986.
Bunn PA, Lichter AS, Makuch RW, Cohen MH, Veach SR, Matthews MJ, Johnston-Anderson A, Edison M, Glatstein E, Minna JD, and Ihde DC. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective randomized trial. Ann Intern Med 106:655–662, 1987.
Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP, Skarin A, Carey RW, Kreisman H, Faulkner C, Comis R, and Green MR. Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung. N Engl J Med 316:912–918, 1987.
Perez CA, Einhorn L, Oldham RK, Greco FA, Cohen HJ, Silerman H, Krauss S, Hornback N, Comas F, Omura G, Salter M, Keller JW, McLaren J, Kellermeyer R, Storaasli J, Birch R, and Dandy M. Randomized trial of radiotherapy to the thorax in limited small cell a preliminary report. J Clin Oncol 2:1200–1208, 1984.
Looney WB, Special lecture: alternating chemotherapy and radiotherapy. NCI Monogr 6:85–94, 1988.
Arriagada R, Le Chevalier T, Baldeyrou P, Pico JL, Ruffie P, Martin M, El Bakry HM, Duroux P, Bignon J, Lenfant B, Hayat M, Rouesse JG, Sancho-Garnier H, and Tubiana M. Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease. Int J Rad Oncol Biol Phys 11:1461–1467, 1985.
Pico JL, Le Chevalier T, Baume D, Arriagada R, Beaujan F, and Hayat M. Phase I-II study of high dose chemotherapy (HDC) followed by autologous bone marrow transplantation (ABMT) in small cell lung cancer. European Society for Medical Oncology. Nice, November 28–30, 1986, abstract no. 225, 1986.
World Health Organization. Handbook for Reporting the Results of Cancer Treatment. WHO Offset, Publ. no. 48. World Health Organization, Geneva.
Cox DR. Regression models and life tables. J R Stat Soc 34:187–220, 1972.
Le Chevalier T, Arriagada R, De The H, De Cremoux H, Sancho-Garnier H, and Rouesse J. Toxicity of first chemotherapy cycle as major prognostic factor in survival of patients with limited small cell lung cancer (LSCLC). Proc Am Soc Clin Oncol 5:181, 1986.
Arriagada R, De The H, Thomas F, Ruffie P, De Cremoux H, Martin M, Duroux P, Dewar J, Sancho-Garnier H, and Le Chevalier T. Limited small cell lung cancer: a possible prognostic impact of initial chemotherapy doses. Bull Cancer 76:605–615, 1989.
Le Chevalier T, Arriagada R, De The H, De Cremoux H, Martin M, Baldeyrou P, Ruffie P, Benna F, Cerrina ML, Sancho-Garnier H, and Hayat M. Combination of chemotherapy and radiotherapy in limited small cel lung carcinoma: results of alternating schedule in 109 patients. NCI Monogr 6:335–338, 1988.
De Cremoux H, Baldeyrou P, Martin M, Ruffie P, Arriagada R, and Le Chevalier T. Late pulmonary toxicity of alternating radiotherapy (RT) and chemotherapy (CT) in limited small cell lung cancer (SCLC). Role of VP 16. Proc Am Soc Clin Oncol, abstract 709,1987.
Johnson BE, Ihde DC, Bunn PA, Becker B, Walsh T, Weinstein ZR, Matthews MJ, Whang-Peng J, Makuch RW, Johnston-Early A, Lichter AS, Carney DN, Cohen MH, Glatstein E, and Minna JD. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Ann Intern Med 103:430–438, 1985.
Henry-Amar M. Quantitative risk of second cancer in patients in first complete remission for early stages of Hodgkin’s disease. NCI Monogr 6:65–72, 1988.
Turrisi AT, Glover DJ, and Mason BA. Concurrent twice-daily radiotherapy plus platinumetoposide chemotherapy for the treatment of limited small cell lung cancer: a preliminary report. In: Treatments Modalities in Lung Cancer, Antibiotics and Chemotherapy, Vol. 41, R Arriagada, and T Le Chevalier (eds). S. Karger, Basel, 1988, pp. 109–114.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Kluwer Academic Publishers, Boston.
About this chapter
Cite this chapter
Chevalier, T.L., Arriagada, R., Tubiana, M. (1992). Combined chemotherapy and radiotherapy in small-cell lung cancer. In: Muggia, F.M. (eds) New Drugs, Concepts and Results in Cancer Chemotherapy. Cancer Treatment and Research, vol 58. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3876-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3876-9_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-7923-1253-6
Online ISBN: 978-1-4615-3876-9
eBook Packages: Springer Book Archive